Advertisement
U.S. markets closed
Advertisement

Reneo Pharmaceuticals, Inc. (RPHM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
6.55+0.21 (+3.31%)
At close: 04:00PM EST
6.67 +0.12 (+1.83%)
After hours: 07:49PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Performance Outlook
Previous Close6.34
Open6.45
Bid6.15 x 1000
Ask7.00 x 800
Day's Range6.32 - 6.75
52 Week Range1.79 - 11.30
Volume761,629
Avg. Volume181,565
Market Cap218.192M
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-2.36
Earnings DateNov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.71
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RPHM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Reneo Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 07/16/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GuruFocus.com

    Reneo Pharmaceuticals Inc (RPHM) Reports Q3 2023 Financial Results

    Anticipation Builds for STRIDE Study Results as R&D Expenses Climb

  • GlobeNewswire

    Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results

    Topline data results from the pivotal STRIDE study are expected in December 2023IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update. “We are looking forward to sharing topline results of our

  • GlobeNewswire

    Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

    IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the following investor conferences. Jefferies London Healthcare Conference Date: Tuesday, November 14 – Thursday, November 16, 2023 Location: The Waldorf Hilton, London, UK Piper